3P Biopharmaceuticals appoints Iker Portugal as Chief Financial Officer

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics incorporates a new member to the management team and appoints Iker Portugal as Chief Financial Officer.

Iker Portugal is an experienced financial manager and joins 3P Biopharmaceuticals with the aim of boosting the company´s growth plans.

Iker comes to 3P with more than 20 years of financial leadership experience. He started his career in 1996 in financial consulting and investment banking and over his extended career he has held a wide range of corporate financial responsibilities, including Investor Relations, Planning & Control or Capital Markets in companies such as the airline technology provider Amadeus, and CFO for the food & drink manufacturer JGC Group. Since mid-2019, and prior to joining 3P, Iker has been a consultant and investor in a Biotech start-up.

Iker graduated in Business and Economics from the University of Navarra, and he holds a Master´s Degree in Economics from the London School of Economics (LSE).

I come to 3P Biopharmaceuticals very excited about the opportunity. 3P is a fast-growing company in an expanding sector: Biotech. Therefore the opportunity for all of us is unique. The fact that our majority partner is Keensight Capital is definitely a plus, as it brings, on the one hand, the expertise of a large fund specialised in Healthcare, and also the capital support that will allow us to grow faster and take advantage of growth opportunities that I am sure will arise“, explained Portugal.

Dámaso Molero, CEO at 3P Biopharmaceuticals said: “We are very pleased to welcome Iker to 3P and incorporate such an experienced leader to our team. I am sure we will have interesting good news coming soon.

I hope that I can contribute to 3P from all my previous experiences and help my colleagues bring the company to a different stage. We are a team prepared for the journey and we keep adding resources to become a leading player in our sector“, added Portugal.

Therefore, with this new addition to the management team, 3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.

Related Content

3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.
Read more

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.
Read more

Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.